Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6124697 | 0.96 | — | — | |
| SCHEMBL20958575 | 0.85 | — | — | |
| SCHEMBL31336435 | 0.83 | CYP2C19 (0.44) | CYP2C19SMN1; SMN2MEN1KMT2ANPSR1 | |
| SCHEMBL3723554 | 0.80 | SMN1; SMN2 (0.46) | CYP2C19SMN1; SMN2MEN1KMT2ANPSR1 | |
| SCHEMBL28216747 | 0.80 | MEN1 (0.48) | SMN1; SMN2MEN1KMT2ANPSR1 | |
| SCHEMBL630719 | 0.78 | MEN1 (0.46) | SMN1; SMN2MEN1KMT2ANPSR1 | |
| SCHEMBL30832481 | 0.77 | MEN1 (0.50) | SMN1; SMN2MEN1KMT2ANPSR1 | |
| SCHEMBL13156117 | 0.77 | MEN1 (0.45) | SMN1; SMN2MEN1KMT2ANPSR1 | |
| SCHEMBL17157174 | 0.77 | — | — | |
| SCHEMBL17171331 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487099-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120107328-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107328-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | CYP2C19 4230/4885SMN1; SMN2 1223/4885MEN1 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.